Fasidotril Eli Lilly.
Lilly is developing fasidotril, a diester prodrug of the active metabolite fasidotrilat, for the potential treatment of hypertension and congestive heart failure (CHF). Phase II trials to investigate the potential of fasidotril for the treatment of hypertension and CHF had commenced by the late 1990s, and were ongoing in July 2003 in the US and Europe.
Department of Pharmacology, Faculty of Medicine, Osmangazi University, Eskisehir 26480, Turkey. fozdener@ogu.edu.tr
Fatih
F
Ozdener
Vural
V
Ozdemir
D000409:Alanine / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000737:chemistry / Q000627:therapeutic use*; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000008:administration & dosage / Q000737:chemistry / Q000627:therapeutic use*; D000959:Antihypertensive Agents / Q000008:administration & dosage / Q000737:chemistry / Q000627:therapeutic use*; D017321:Clinical Trials, Phase I as Topic; D017322:Clinical Trials, Phase II as Topic; D006333:Heart Failure / Q000188:drug therapy* / Q000201:enzymology; D006801:Humans; D006978:Hypertension, Renovascular / Q000188:drug therapy* / Q000201:enzymology; D015394:Molecular Structure; D011480:Protease Inhibitors / Q000008:administration & dosage / Q000737:chemistry / Q000627:therapeutic use*; D016032:Randomized Controlled Trials as Topic; D013329:Structure-Activity Relationship
D000806:Angiotensin-Converting Enzyme Inhibitors; D000959:Antihypertensive Agents; D011480:Protease Inhibitors; C097293:aladotril; D000409:Alanine